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ABSTRACT 
 
Estrogens may influence bone growth locally or systemically via the estrogen receptors alpha 
(ERα), beta (ERβ) and G protein-coupled estrogen receptor 1 (GPER-1). In Paper I, our 
study showed that the treatment of ovariectomized C57BL/6 mice with a selective ERα 
agonist 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole (PPT) reduced growth plate height 
and hypertrophic zone height suggesting that the effect was induced via ERα. Furthermore, 
chondrocyte proliferation in the growth plate was also inhibited by 17β-estradiol (E2) or PPT 
as evaluated by proliferating cell nuclear antigen (PCNA) staining. Furthermore, tibiae and 
femur bones were shorter in E2- or PPT-treated mice when compared to vehicle-treated 
controls. In contrast, bone lengths in mice treated with a selective ERβ agonist 2,3-bis(4- 
hydroxyphenyl)-propionitrile (DPN) were similar to bone lengths in controls. These results 
showed that estrogenic effects on bone growth and growth plate maturation are mainly 
mediated via ERα. In contrast, the selective GPER-1 agonist G1 had no effects on either 
metatarsal bone growth ex vivo or tibia and femur growth in treated metatarsals or mice when 
compared to control groups. Thus, the results from Paper I and II demonstrated that, ligand 
stimulation of GPER-1 and ERβ does not influence bone growth in mice.  
In Paper III, target genes and signaling pathways affected by E2 were identified. The 
enriched pathways inhibited by E2 included estrogen response early and late, apoptosis, 
epithelial mesenchymal transition and angiogenesis. Also, the mammalian target 
of rapamycin (mTOR) signaling pathway, which regulates chondrocyte proliferation and 
differentiation, was significantly inhibited by E2. Among the most strongly affected genes, 
the expression of peptide YY, a negative regulator of bone formation and mineral density, 
was inhibited by E2 treatment. Furthermore, epidermal growth factor and oxidative 
phosphorylation signalling pathways and subgroups of genes regulated by Myc and genes 
important for mitotic spindle assembly were among the enriched pathways upregulated by E2. 
Our data showed that E2 actions on bone growth and growth plate maturation are mainly 
mediated via ERα. In contrast, ligand stimulation of either ERβ or GPER-1 did not influence 
bone growth in mice. Also, our study has identified target genes and pathways influenced by 
E2 in the growth plate. Further studies are required to determine the specific mechanisms 
involving E2-regulated genes. Our findings may have direct implications for the development 
of new and more selective treatment modalities of extreme tall stature using selective ER 
modulators that may have fewer side effects than high-dose E2 treatment. 
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1  INTRODUCTION 
1.1 PHYSIOLOGY AND STRUCTURE OF THE GROWTH PLATE 
1.1.1  Functional morphology of the growth plate 
Longitudinal bone growth originates in the epiphyseal growth plate and is regulated by various 
mechanisms, which control the size and the shape of the body [1]. The growth plate is not 
vascularized and is formed by chondrocytes surrounded by extracellular matrix (ECM). The 
growth plate closure in most species follows skeletal maturation. The primary phase of 
longitudinal bone growth includes deposition of cartilage. This process is followed by cartilage 
degradation caused by calcification and infiltration by bone-building cells, which construct 
osseous tissue. These mechanisms of degeneration and regeneration take place within the 
growth plate located between the epiphysis and metaphysis at the ends of the long bones [2]. 
Histologically, the growth plate is mostly formed by chondrocytes located in columns along 
the axis of the bone. There are three different zones in the growth plate containing cells with 
different stages of differentiation [3]. These zones include: a) the resting zone, formed by stem 
cells; b) the proliferative zone, containing flat cells; c) the hypertrophic zone, containing 
hypertrophied cells. During endochondral ossification, newly generated cartilage develops into 
the bone tissue. The direction and degree of the growth depend on the processes of proliferation 
and the activity of extracellular matrix. The cells of the resting zone serve as a constant supply 
for bone growth. The chondrocytes of the resting zone eventually migrate to the proliferative 
zone, where they elevate their division rate. Moreover, in the proliferation zone, the 
chondrocytes form dense cellular columns. The spatial orientation of these columns dictates 
the future direction of the bone growth. In the hypertrophic zone, chondroblasts differentiate 
into hypertrophic chondrocytes by undergoing significant phenotypic changes [4]. These 
transitional changes include cytoplasm expansion and upregulation of cartilage matrix genes at 
mRNA level. 
 
1.1.2 Regulation of chondrocyte proliferation and hypertrophy 
After undergoing hypertrophy, chondroblasts cease the expression of matrix genes and 
differentiate into prechondrocytic cells under control of Sex-determining region Y-related 
high mobility group box 5 (Sox5) and Sox6 [5]. Chondroblasts also proliferate under the 
control of Runx2, which regulates the positioning of columns by mediating cell proliferation. 
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Moreover, Runx2 was found to be active in hypertrophic chondrocytes, but was suppressed in 
chondroblasts [6]. Thus, Runx2 is considered as an activator of maturation markers expressed 
by chondrocytes. After the increased division in the proliferative zone, the chondrocytes 
abandon cell cycle and commence to augment in the hypertrophic zone. Ultimately, the 
chondrocytes become apoptotic and enhanced tissue vascularization and calcification adjourn 
the growth plate activity.  
 
 
 
Figure 1. Regulatory gene expression in the growth plate zones and the perichondrium [7]. There 
is a variety of physiological genes and signaling pathways regulating chondrogenesis. These growth 
regulators include Hedgehog, bone morphogenic proteins (BMPs), fibroblast growth factors (FGFs) and 
vasculogenic signaling pathways. 
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1.2 LOCAL AND SYSTEMIC FACTORS REGULATING BONE GROWTH 
1.2.1 Nutrition, exercise and bone health 
Nutrition and exercise are the two factors, which are vital for bone development and bone 
health. The importance of the key nutrients, such as calcium, magnesium, phosphorus, 
potassium and other microelements and vitamins D, A, K, C and B has been emphasized by 
multiple studies [8]. Vitamin D regulates calcium and phosphate absorption and calcium 
release from the bone [9]. In line with this, vitamin D deficiency induces rickets and 
osteomalacia, which are represented by impaired mineralization during skeletal development 
and adulthood, respectively [10]. Moreover, lack of vitamin D blocks chondrocyte maturation 
followed by chondrocyte hypertrophy and broadening of the growth plates. 
Exercises have been shown to protect bone health against skeletal disorders, such as 
osteoporosis [11]. Physical activity might positively influence bone health by affecting multiple 
factors, such as release of hormones, cytokine secretion and activation of regulatory signaling 
pathways. In particular, exercises were shown to activate the production of several hormones 
regulating bone growth such as estradiol (E2) and parathyroid hormone (PTH). Moreover, there 
was a clear correlation between exercises characterized by elevated forces applied on the body 
and increased bone mass density and strength [12]. Also, physical exercises have been 
demonstrated to enhance bone formation [13]. Furthermore, mechanical loadings caused by 
exercises activate osteoblast differentiation and regulate bone metabolism [14].  
 
1.2.2 Systemic factors regulating bone growth 
Bone growth and metabolism are regulated by a spectrum of various hormones. Thyroid, 
parathyroid and sex hormones show the most notable effects. Among them, thyroid hormones 
play a crucial role in the development, growth and metabolism of bone tissue. The expression 
of thyroid receptors was found in the chondrocytes located in the proliferative zone of the 
growth plate and osteoblasts [15]. Being the main regulator of calcium and phosphate levels, 
PTH influences bone homeostasis acting via specific receptors expressed by osteoblasts. 
Several in vivo studies have demonstrated that PTH enhances bone growth via stimulation of 
proliferation and inhibition of apoptosis in osteoblasts and their precursors [16]. 
Among other hormonal factors, growth hormone (GH)/insulin-like growth factor 1 (IGF-1) 
axis is vital for the longitudinal bone growth. During prepubescence, GH is similarly produced 
in boys and girls. However, both GH and IGF-1 production raises earlier in girls than in boys 
during puberty [17]. Under the regulation by GH produced in the hypophysis, the hepatocytes 
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secrete IGFs, which regulate the bone and cartilage physiology. Noticeably, both GH and IGF-
1are locally produced by osteoblasts and chondrocytes [18]. Both GH and IGF-1 deficient 
animal models demonstrate diminished periosteal and longitudinal bone growth. Furthermore, 
GH receptor or IGF-1 receptor deficient models showed that GH regulates synthesis of IGF-1 
in the liver and IGF-1 exert its effects both locally and systemically.   
Also, androgens were shown to enhance longitudinal bone growth. The effects of androgens in 
the bone are mediated via androgen receptors (ARs) expressed in both osteoblasts and 
osteocytes [19]. Moreover, ARs, which were detected in osteocytes, are involved in the 
regulation of skeletal integrity [20]. An impaired bone development due to affected osteoblasts 
differentiation was found AR-deficient mice [21]. Furthermore, selective androgen receptor 
modulators (SARMs), which stimulate ARs, were demonstrated to elevate BMD and bone 
strength in animal models [22]. In contrast, a study by our group has shown that AR modulation 
by neither androgens nor the selective AR inhibitor affect growth of rat metatarsal bones in 
vitro [23]. 
1.2.3  Signaling pathways regulating bone growth  
Differentiation of chondrocytes is a crucial step in bone development. A plethora of local and 
systemic regulatory signaling factors, which control the differentiation of chondrocytes from 
mesenchymal progenitors to mature hypertrophic chondrocytes, includes Indian hedgehog 
protein (Ihh), fibroblast growth factors (FGF), SRY-related high-mobility group-box gene 9 
(Sox9), bone morphogenic proteins (BMP), parathyroid hormone-related peptide (PTHrP), and 
others (Fig. 1). 
Among these factors, Indian Hedgehog (Ihh) is one of the key regulators of osteoblast 
differentiation. The expression of Ihh was found in the prehypertrophic chondrocytes in the 
growth plate. The interplay between Ihh and parathyroid hormone-related peptide (PTHrP) 
regulates the differentiation processes in the growth plate and longitudinal bone growth [24]. 
In particular, Ihh activates PTHrP expression in chondrocytes. As a consequence, PTHrP is 
transported to the growth plate to stimulate chondrocyte proliferation. Further, chondrocytes 
halt the cell cycle and proceed to hypertrophy when PTHrP expression declines [25]. Also, 
previous studies have shown that Ihh-deficient mice have increased numbers of hypertrophic 
chondrocytes caused by early migration of chondrocytes from the group of proliferating growth 
plate cells. This event is induced by the inability of the cartilage in Ihh-deficient mice to 
produce PTHrP. Moreover, since Ihh is necessary for osteoblast development, these mice show 
decreased osteoblast fraction [26]. In addition, the bone development depends on the 
interactions between Ihh and Wnt/β-catenin signaling. Moreover, overreactivity of Ihh and 
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Wnt/β-catenin signaling leads to either deficient bone growth due to osteoporosis or 
ossification loci in different tissues. 
In addition to Ihh pathway, fibroblast growth factor (FGF) signaling is an important pathway 
controlling chondrocyte expansion and differentiation. During chondrocytes development, 
FGF receptor-3 (FGFR3) is expressed in proliferating cells, while FGF receptor-1 is detected 
in hypertrophic cells. Also, FGF receptor-3-deficient mice demonstrate an enhanced 
chondrocyte proliferation [27]. Moreover, mutations in human FGFR3 suppress chondrocyte 
proliferation and induce disorganization of chondrocyte columns [28]. Several studies have 
shown that FGFR3-mediated suppression of proliferation by FGF is regulated via stimulation 
of JAK-STAT1 signaling pathway [29]. Overall, FGF makes chondrocyte columns shorter by 
suppressing proliferation and Ihh expression. 
 
1.2.4 Functions of BMPs, VEGFs and mTOR in the regulation of bone 
growth  
Also, bone morphogenic proteins (BMPs), which belong to the TGFβ family of transcription 
factors, are vital for cartilage and bone development. Signaling by TGF-β/BMPs includes 
Smad-dependent and Smad-independent pathways. The development of skeleton involves the 
activation of both Runx2 and TGF-β/BMPs-stimulated Smads [30]. The expression of BMP 
family members, BMP2, -6 and -7 was found in both proliferating and hypertrophic 
chondrocytes. Treatment with BMPs was demonstrated to elevate chondrocyte proliferation 
and suppress differentiation of hypertrophic chondrocytes [31, 32]. Noticeably, BMP and FGF 
signaling pathways demonstrate antagonistic effects on cellular  proliferation in the growth 
plate [33]. As a growth activator, exposure to BMP2 stimulated chondrocyte proliferation 
primarily reduced in a mouse model of achondroplasia [31]. BMP proteins were shown to 
activate condensation of mesenchymal stem cells and enhance chondrocyte proliferation.  
 
Although chondrocytes and osteoblast belong two distinct cellular lineages, the precursors of 
osteogenic and chondrogenic cell lineages were found to differentiate from mesenchymal stem 
cells under the regulation of multiple transcriptional factors [34, 35]. Thus, mesenchymal stem 
cells demonstrate high chondrogenic potential (Fig. 2). In contrast, bone resorbing osteoclasts 
might originate from the bone marrow hematopoietic stem cells [36]. 
 
In addition, the mechanisms of bone remodeling are controlled by growth factors, such as 
vascular endothelial growth factor (VEGF), which are crucial for regulation of vasculogenesis 
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in the bone. With regard to bone formation, VEGF is known to stimulate cartilage development 
and its replacement by bone [37]. Furthermore, mTOR signaling pathway has recently been 
found to be important for bone development, since mTOR deficiency led to bone growth 
impairment [38]. Moreover, activation of chondrocyte proliferation and suppression of 
terminal differentiation by mTORC1 has recently been shown [39]. In addition, the mice 
deficient in TSC1, a suppressor of mTOR, showed increased chondrocyte proliferation but 
inhibited chondrocyte differentiation. 
The extracellular matrix of the growth plate consists of collagen types II, VI, X, and XI and 
proteoglycans. Collagen type X is produced by hypertrophic chondrocytes in the part of the 
growth plate which undergoes matrix calcification [40, 41]. 
 
 
 
 
Figure 2.  Currently known regulators of chondrogenic proliferation and differentiation from 
mesenchymal stem cells. The regulatory factors include transcription factors, signaling molecules and 
microRNAs. Positive regulatory factors are shown in green, while the inhibitory regulators are shown 
in red [7]. 
 
 
1.2.5 ESTROGENS AND THEIR RECEPTORS IN THE BONE 
Sex hormones are known to influence bone growth and metabolism. It is well established that 
trabecular bone mass notably diminishes during menopause; however, this mechanism can be 
suppressed by estrogen treatment. Recent studies indicate that estrogens play an essential role 
in maintaining bone homeostasis also in men. Furthermore, E2 was suggested to regulate BMD 
in men, since raloxifene, a selective ER modulator, elevated BMD in hip and spine in male 
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patients [42]. In line with these findings, aged male patients, who were treated with an 
aromatase inhibitor anastrozole, had enhanced bone resorption and suppressed markers of bone 
development [43]. 
 
1.2.6 Effects of E2 on bone growth 
Predisposition of men to bone loss and fractures might be related to variability in Cytochrome 
P450 Family 19 Subfamily A Member 1 (CYP19A1), which modifies serum E2 levels. Also, 
an association of a single-nucleotide polymorphism in CYP19A1 with increased E2 levels was 
observed in men [44].   
Moreover, E2 decreases the degree of bone remodeling and assist to keep the equilibrium 
between bone resorption and development. These functions are mediated via the regulation of 
osteoblast and osteoclast proliferation. Besides, estrogens influence the growth of both 
osteoblasts and osteoclasts by inducing apoptosis in osteoclasts and inhibiting this process in 
osteoblasts. Decreased levels of E2 induce loss of bone tissue accompanied by the enhanced 
bone remodeling, elevated osteoblasts and osteoclasts counts and bone resorption [45]. Many 
physiological processes, including growth, development and differentiation, are regulated by 
estrogens. The main estrogen, E2, is primarily synthesized in the ovaries in premenopausal 
women, while in men and postmenopausal women E2 is converted from testosterone and 
androstenedione in extragonadal tissues [46]. Besides the effects on normal cells, E2 is also 
involved in various pathological processes, including malignancies [47].  
 
1.2.7 Regulation of GH/IGF-1 signaling in bone by estrogens  
Studies in vitro and in vivo have shown that estrogen can be produced by chondrocytes [48-
51]. This is in line with the observations of P450 aromatase expression in both human [48] and 
rat [50, 51] growth plates. Besides, the locally produced estrogen is suggested to regulate 
proliferation of chondrocytes and to prevent chondrocytes from undergoing apoptosis [51]. In 
particular, low levels of E2 stimulate bone growth during early puberty, while high levels 
during late maturation suppress bone growth by inducing growth plate fusion [52]. Since E2 is 
known to influence the GH/IGF-1 pathway, the regulation of bone growth by E2 might be 
partially mediated via the effects on the GH/IGF-1 axis [53]. 
Notably, suppression of IGF-1 was observed in male ERα-deficient mice and aromatase 
inhibitor-exposed mice in spite of enhanced androgens, which suggested that androgens might 
regulate IGF-1 through stimulation of ERα and aromatization. In addition, E2 was shown to be 
 14 
a crucial regulator of IGF-1 production in the liver of male GH-receptor-deficient mice, since 
E2 completely revived periosteal bone growth in these animals [54]. Thus, several studies have 
proved that the interactions between estrogens and the GH-IGH-1 pathway are vital in the 
determination of sexual dimorphism during puberty. Post-pubertal effects of estrogens via GH-
IGF-1 remain to be verified.  
 
1.2.8 Structure and functions of nuclear and membranous estrogen 
receptors 
The nuclear estrogen receptors alpha (ER) and beta (ER) are the main receptors mediating 
the effects of E2 [55].  Originally, ER expression was found in the rat uterus in 1964 and 
extensively characterized afterwards [56]. In contrast, ER, another nuclear E2-binding 
receptor, was discovered in the rat prostate two decades later [57]. Both receptors were reported 
to act as transcription factors that bind estrogen response elements (ERE) in the E2-regulated 
genes. 
Structurally, both ER and ER consist of three domains: the NH2-terminal domain (NTD), 
the DNA-binding domain (DBD), and the ligand binding domain (LBD) [58] (Figure 1). The 
NTD contains an activation function (AF-1) region regulating ligand/independent 
transcriptional activation of target genes. The DBD regulates the binding of the ERs to the 
target DNA sequences called ERE. Upon binding to EREs, the ERs affect transcription of target 
genes. Alternatively, ERs regulate gene expression by interacting with the transcription factors, 
including the specificity protein 1 (Sp1), the activator protein 1 (AP1), nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) and p53 [59]. In addition to direct effects on 
gene transcription, the ERs are involved in rapid cytoplasmic activation of phospholipase C 
and protein kinase pathways [60].  
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Figure 3. Structure of human ERα and ERβ and overview of ER ligand-dependent and ligand-
independent signaling pathways. (A) Structural and functional ER domains: DNA-binding domain, 
hinge domain, ligand-binding domain and transcriptional activation domains AF-1 and AF-2. (B) ER 
ligand-dependent (green arrows) and ligand-independent (red arrows) signaling. 
 
Although ER and ER bind E2 with similar affinity, structural differences in the LBD domain 
allowed to develop subtype-specific selective ligands for ER and ER [55]. Selective ER 
agonists are effectively used to identify the specific functions of the ERs. In particular, propyl 
pyrazole triol (PPT) has a 410-fold selectivity for ER versus ER [61]. With regard to ER, 
2,3-bis(4- hydroxyphenyl)-propionitrile (DPN) is a selective ER agonist which has a 70-300-
fold selectivity and is widely used to study the functions of ER [62, 63]. Following the ligand-
dependent binding, the nuclear ERs compose homodimers or heterodimers. Animal and in vitro 
studies have shown different transcriptional effects of ER and ER [64] and different cellular 
reactions for each specific ligand [65].  
In addition to the differences in transcriptional responses, the distribution of the ERs varies in 
different tissues. While ER expression is mainly observed in the uterus, ovaries, breast, 
kidney, adipose tissue and liver, ER is primarily found in central nervous system, 
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cardiovascular system, lung, male reproductive organs, prostate, colon, kidney and immune 
system [55, 66]. With regard to bone, both ER and ER are highly expressed in the growth 
plate [67]. 
In addition to nuclear ERs, membrane-expressed GPER-1 was demonstrated to bind E2 with 
high affinity in vitro [68] and was originally identified in lung, heart, brain and lymphoid tissues 
[69, 70] and breast cancer and Burkitt's lymphoma cell lines [70, 71]. Previous studies have 
shown that activation of GPER-1 by E2 or selective GPER agonists activates cAMP production 
and proto-oncogene tyrosine-protein kinase Src, leading to the stimulation of MMPs. A series 
of the following events leads to the activation of MAPK and PI3K/Akt signaling pathways 
resulting in changes in gene transcription [72]. 
With regard to the bone, GPER-1 was found to be expressed in the epiphyseal growth plate 
with the highest level of expression in hypertrophic chondrocytes [73]. Moreover, the 
expression of GPER-1 was found in human osteoblasts, osteoclasts, and osteocytes [74]. This 
membrane ER is involved in rapid non-genomic E2 signaling and is highly expressed in the 
hypertrophic zone of the bone growth plate. 
The expression of GPER-1 is downregulated toward puberty, indicating that GPER-1 may be 
involved in the regulation of longitudinal bone growth [73]. Moreover, GPER-1 may mediate 
E2 effects in the growth plate, since E2 does not affect bone growth height and bone length in 
the GPER-1-/- mice [75]. 
 
1.2.9 ER target genes and pathways in bone 
Although the target genes regulated by estrogens in the bone have not been clearly identified, 
E2 has been demonstrated to suppress the bone resorption through ephA2/ephrinA2 signaling 
pathway [76]. Furthermore, the protective effect of E2 on cartilage via ERK-mammalian target 
of rapamycin (mTOR) signaling has also been shown [77].  
In addition to the effects on bone remodeling, the development of osteoporosis has been known 
for decades to be highly dependent on E2 levels. A potential mechanism of osteoporosis might 
be related to the lower sensitivity of bone tissue to mechanical loading. The decrease in 
sensitivity in this case is caused by E2 deficiency. In line with this statement, ERα is known to 
stimulate the sensitivity of bone to mechanical loading by stimulation of the Wnt signaling 
[78], although the influence of ERα on mechanical loading did not necessitate ligand binding. 
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1.2.10   ERα target genes in osteoblasts 
With regard to ERα target genes in osteoblasts, ChiP-on-chip analysis has revealed that ERα 
regulates the expression of a large number of crucial osteoblast genes, such alkaline 
phosphatase Alpl, receptors GPER-1 and Nr5a2 and several transcription factors (Pax7 and 
Sox5) [79]. Also, the IGF binding protein 4 (IGFBP4) was proved to be an ERα target, which 
demonstrates the interactions between ER and IGF signaling [80]. In addition, ERα-mediated 
effects on matrix metalloproteinase 3 influence FasL-mediated apoptosis in osteoclasts [81]. 
High doses of E2 were shown to decrease height in young females with constitutional tall 
stature [82, 83]. However, therapy with high doses of E2 may have potential side effects, 
including decreased fertility [84], elevated risk of breast and ovarian cancers [85, 86], 
malignant melanoma [86] and vein thrombosis [87]. On the contrary, inhibition of E2 synthesis 
with an aromatase inhibitor increased predicted adult height in young patients with idiopathic 
short stature [88]. Although, treatment with an aromatase inhibitor was shown to increase the 
prevalence of vertebral deformities [89].  
 
1.2.11  Effects of SERMs on bone growth 
Several generations of selective estrogen receptor modulators (SERMs) are currently available 
for treatment of bone growth disorders. Tamoxifen, a first-generation SERM, is used in the 
treatment of breast cancer [90]. In addition to anti-cancer applications, tamoxifen was used to 
treat young males with gynecomastia [91, 92] and McCune-Albright syndrome [93]. With 
regard to the effects on bone growth, tamoxifen had either no effect or decreased longitudinal 
growth [91-93]. In addition, tamoxifen was shown to suppress the growth of longitudinal bones 
in young male rats by increasing chondrocyte apoptosis, decreasing growth plate height and 
the levels of IGF-I [94].  Moreover, tamoxifen decreased both endosteal and periosteal bone 
growth in young male rats [94]. These results suggest that treatment with tamoxifen may 
negatively affect bone growth in young patients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
With regard to other SERMS, raloxifene acts as an ER agonist in bone and is used to prevent 
postmenopausal osteoporosis. Also, it was shown to suppress longitudinal bone growth in rats 
[95]. However, it accelerates epiphyseal fusion in ovariectomized (OVX) rabbits [96]. 
In addition, aromatase-deficient male patients were found to have decreased bone mass. Since 
aromatase mediates conversion of androgens into estrogens, estrogen was suggested to regulate 
the development of male bones [97]. In male skeleton, the local production of estrogens from 
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testosterone is catalyzed by aromatase and supports protective functions of estrogens. Notably, 
aromatase-deficient individuals demonstrate symptoms of osteoporosis and unclosed 
epiphyses similarly to patients lacking ERα [98].  
 
1.3 FUNCTIONS OF THE ERS IN THE REGULATION OF BONE GROWTH 
1.3.1  ER is the predominant ER in bone 
Several studies of patients with inactive ERα gene or aromatase deficiency suggested that E2 
regulates growth plate closure [99-102]. In addition, a clinical report of an 18-year-old female 
patient with mutated ERα gene indicated that ERα mutations might induce E2 resistance. 
Moreover, the clinical symptoms of the patient with the ERα mutation were similar to the 
abnormalities found in the phenotypical changes in the mouse ERα knockout [102].  
In addition to clinical data, studies using ER, ER and GPER-1 deficient mouse models 
showed that the effects of E2 in both trabecular and cortical bone are mainly mediated through 
ER. OVX mice were shown to lose bone mass, which can be restored by E2 treatment. 
However, in ER-/- mice treatment with E2 did not restore the bone mass, suggesting the 
importance of ER for bone growth [103]. 
In contrast, both ER and GPER-1 were not shown to be important for mediating estrogenic 
effects on bone growth [103]. The studies using female ERβ-/- mice demonstrated that ER has 
only moderate effects in bone by modulating ER actions in female mice [103]. Moreover, 
studies in ERα-/-, ERβ-/- and ERαβ-/- mice found that ER inhibits ER-mediated gene 
transcription in bone when ER is expressed [104]. 
Estrogens are proposed to affect bone growth and growth plate closure either via GH and IGF-
I or via ER which is highly expressed in the chondrocytes of the growth plate (Fig. 4) [103]. 
Thus, low levels of E2 in early sexual maturation stimulate bone growth through the GH/IGF-
I axis, while the high levels of E2 during late sexual maturation or exposure to high doses of 
E2 suppress bone growth directly by activating ERα locally expressed in the growth plate. 
A mouse model with selective knock-out of ER in cartilage (Col2α1-ERα-/-) was generated 
to study these bone growth regulatory pathways [105]. Comparison of male ER-/- and male 
Col2α1-ERα-/- mice showed a reduction of bone growth in ER-/- mice, while the bone length 
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was not affected in Col2α1-ERα-/- mice [105]. The suppressed bone growth in male ER-/- mice 
correlated with decreased serum concentration of IGF-I and reduced GH secretion, suggesting 
that in male mice the GH/IGF-I pathway mediates the regulation of bone growth via ER and 
does not require ER expression in the growth plate [18].  
To study the potential functions of local ERα in the process of growth plate closure, 
gonadectomized Col2α1-ERα-/- mice were exposed to a high dose of E2. No changes were 
detected in Col2α1-ERα-/- mice, while the vehicle-treated group showed shortened growth plate 
height in response to E2 treatment. These results suggested that the growth plate height in both 
male and female mice is reduced by the E2 action via locally expressed ERα. Also, knock-in 
mice with an ERα impaired of DNA binding (NERKI mice) showed several bone 
abnormalities, such as defective bone development [106] and suppressed osteoblast activation 
markers [107]. In addition, ER, locally expressed in the growth plate, was shown to mediate 
age-related decrease of longitudinal bone growth, since both female Col2α1-ERα-/- and female 
ERα-/- showed continued longitudinal bone growth [105, 108]. 
 
 
Figure 4. The role of ERα in longitudinal bone growth. The regulation of bone growth by ERα 
includes two potential mechanisms: a. Indirect GH/IGF-I-mediated effects, which regulate bone growth 
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during early puberty associated with low serum E2 levels and do not involve ERα in the growth plate, 
and b. Direct actions of locally expressed ERα, which is activated by high doses of E2 and suppresses 
growth plate height in mature mice and longitudinal bone growth in elderly mice. + Stimulatory effects, 
- suppressive effects [108].   
 
Growth plate closure in rodents may be induced by high doses of E2 [109]. To study the 
involvement of local ER in the mechanisms regulating growth plate closure, male and female 
Col2α1-ERα-/- and WT mice were castrated and treated with high doses of E2 or vehicle. Both 
Col2α1-ERα-/- and WT mice showed similar effects of E2 on bone mass and uterus [105]. While 
WT mice had decreased growth plate height in response to E2 treatment, Col2α1-ERα-/- mice 
did not show any changes in growth plate size after they were treated with E2, indicating that 
reduction of growth plate height by E2 involves ER, locally expressed in chondrocytes [105]. 
In addition, the histological evaluation of growth plates in WT mice revealed that the reduction 
of the growth plate height was related to a decrease of the proliferative zone with the size of 
the hypertrophic zone being unchanged. In contrast, no reduction was observed in either the 
proliferative or hypertrophic zones in the growth plates in Col2α1-ERα-/- mice [105]. 
Interestingly, the mice with an inactivation of AF-1 (ERαAF-10) also showed a decreased size 
of the proliferative zone before closure of the growth plate, indicating that the senescence of 
the growth plate is regulated via local ER independently of ER AF-1. [108]. These findings 
in mouse models, including Col2α1-ERα-/- mice, indicate that ER, expressed in the growth 
plate, may be crucial for growth plate senescence in humans and that the reduction of bone 
growth induced by high levels of E2 is mediated directly through locally expressed ER [105]. 
Thus, ER, expressed in growth plate chondrocytes, is suggested to be the main ER regulating 
growth plate senescence and cessation of longitudinal bone growth. 
The actions of ERα in the bone might also depend on the involvement of ERα AF-1 and AF-2. 
In particular, gonadectomized AF-2-deficient mice do not respond to E2 treatment, suggesting 
the important functions of ligand-activated AF-2 in bone physiology [110].   
 
1.3.2 Functions of ERβ in bone 
No effects of ERβ on bone growth were observed using knockout models, since no bone 
impairments were found in male ERβKO mice [111]. Moreover, the trabecular response to E2 
in OVX female ERβKO mice was found to be normal [112]. The expression of was found in 
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cancellous bone, while no was detected in cortical bone tissue [113]. A few studies have shown 
increased of longitudinal bone growth and decreased bone resorption, which was associated 
with elevated ERα RNA expression, in female ERβKO mice [114, 115]. In addition, decreased 
trabecular bone loss and enlarged cortical bone area have been detected in OVX ERβKO mice 
over long-term observation [116]. Moreover, ERβ-deficient mice showed faster regeneration 
after fracture [117]. Also, the mice with ERβ-deficient bone cells had enlarged trabecular bone 
volume [107]. A recent study has shown that in femoral bone tissue mRNA expression of 
several genes, which were affected by ovariectomy, was restored by the treatment with the 
selective ERβ agonist DPN. The study indicated that ligand-activated ERβ might regulate bone 
biology [118].  
Among the membranous and nuclear ERs, ERα appears to be the predominant regulator of E2 
effects on bone growth. Furthermore, ERβ demonstrates moderate inhibitory effects on ERα 
effects. However, the functions of ERβ in growth plate remain to be identified.  
 
1.3.3 Functions of GPER-1 in bone 
Membranous ER, GPER-1, might also play an important role in the regulation of bone growth. 
The regulation of rapid E2-mediated activation of signal-regulated kinases via this receptor, at 
that time known as GPR30, was initially demonstrated in 2000 [119]. Accumulated data 
indicated that GPR30 was an E2-binding receptor, which led to its entitlement as GPER-1 in 
2007. Although, the functions of GPER-1 have been determined for various tissues, its effects 
in the bone remain to be uncovered. Notably, lower body weight, shorter body length and 
lowered IGF-1 in serum were observed in female GPER-1-KO mice [120]. In addition, 
ovariectomy prevented E2-regulated growth plate closure in GPER-1-deficient mice [75]. 
Also, another study found suppressed growth plate closure in GPER-1-KO mice [121]. The 
development of puberty was shown to negatively correlate with GPER-1 expression in the 
human growth plate [73]. Thus, the functions of ERβ and GPER-1 on human bone growth 
remain to be identified.   
 22 
2 AIMS OF THE THESIS  
Sex hormones are known to affect longitudinal bone growth. Recent studies demonstrate that 
estrogens play an important role in maintaining bone homeostasis. The effects of estrogens are 
mediated via estrogen receptors. All three main estrogen receptors, ERα, ERβ and GPER-1 are 
expressed in the growth plate. However, their functions in bone physiology have not yet been 
determined. Also, the target genes of E2 in the growth plate chondrocytes are not well known. 
The overall aim of this thesis was to investigate the ER-mediated effects of E2 in the growth 
plate cartilage. 
 
The specific aims of this work were: 
 
 To investigate the functions of ERα and ERβ on bone growth and in the growth plate 
cartilage (Paper I).  
 To study the effects of activated GPER-1 on bone growth and in the growth plate 
cartilage (Paper II). 
 To identify target genes and signaling pathways affected by E2 in human growth plate 
cartilage (Paper III).  
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3 MATERIALS AND METHODS 
3.1 MATERIALS FOR IN VIVO AND EX VIVO STUDIES 
3.1.1 MICE 
For in vivo experiments, twelve-week-old female C57BL/6 mice (n = 9–10/group) and four-
day-old mouse pups C57BL/6 were purchased from Charles River Laboratories. The adult 
animals were housed in the animal facility at the University of Gothenburg and kept in 12-h 
day and night condition with standard chow and tap water ad libitum. 
 
3.1.2  METATARSAL CULTURE  
For ex vivo organ cultures, the three middle metatarsal bones obtained from four-day-old 
mouse pups C57BL/6 were dissected out from each hind paw and cultured as described below.  
 
3.1.3 PATIENTS 
 
Human growth plate tissue samples were obtained from one 12-year and 3-month-old girl and 
one 13-year and 5-month-old boy, who underwent epiphyseal surgery due to constitutional tall 
stature. Growth plate biopsies from the proximal tibia and distal femur were taken using bone 
marrow biopsy needles (7 gauge; Gallini Medical Products and Services, Modena, Italy). The 
study was approved by the local ethics committee at Karolinska University Hospital, 
Stockholm, Sweden (ethical permit number: 97-214). The informed consent was obtained from 
both the patients and their parents. 
 
3.1.4  REAGENTS 
 
17β-estradiol-3-benzoate (E2) was purchased from Sigma-Aldrich and the ERβ-selective 
agonist DPN (2,3-bis (4-hydroxyphenyl) propionitrile) and the ERα-selective agonist PPT 
(1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole) were obtained from Tocris Bioscience 
(Bristol, UK). G protein-coupled estrogen receptor 1 (GPER-1) selective agonist G1 was 
obtained from Merck Chemicals. 
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Bovine serum albumin (BSA), β-glycerophosphate disodium salt hydrate and 17β-estradiol-3-
benzoate (E2) were purchased from Sigma-Aldrich. Phosphate buffered saline (PBS), 
DMEM/F12 phenol red-free medium and gentamycin were bought from Invitrogen. l-Ascorbic 
acid A4403 and β-glycerophosphate disodium salt hydrate G 9422 were purchased from Sigma.  
Primary rabbit anti-PCNA antibody (RbPAb + PCNAab 18197) was provided by Abcam. 
Normal donkey serum and secondary CY3-conjugated AffiniPureF (ab) Fragment Donkey 
Anti-Rabbit IgG antibody were purchased from Jackson ImmunoResearch Laboratories. 
Fluorescence mounting medium was obtained from Dako. 4′,6-diamidino-2-phenylindole 
dihydrochloride (DAPI) was purchased from Sigma-Aldrich. 
 
3.2  METHODS 
3.2.1 Ovariectomy and treatment 
 
Mice were randomized into 5 different groups. Four groups were OVX and one group was 
sham-operated. Both ovariectomy and sham operations were performed at twelve weeks of age 
under intraperitoneal anesthesia with ketamine (Ketalar; Pfizer) and medetomidine (Domitor; 
Orion Pharma, Espoo, Finland). Carprofen (Orion Pharma) was used postoperatively for pain 
relief. A midline incision was followed by flank incisions of the peritoneum, and the ovaries 
were removed with sterile scissors. The skin incision was closed with metallic clips. The sham-
operated mice were treated in the same way, except that the ovaries were not removed. Sham-
operated mice were subcutaneously (s.c.) injected with 100 μL of vehicle (10% ethanol and 
90% Miglyol 812, Omya Peralta, Hamburg, Germany) (n = 10). The OVX mice were treated 
s.c. with 100 μL of E2 (1 µg/mouse; 0.04 mg/kg/day) (n = 9), PPT (175 µg/mouse; 7 
mg/kg/day) (n = 10), DPN (105 µg/mouse; 4.2 mg/kg/day) (n = 10) or vehicle (n = 10). All the 
groups received injections 5 days per week for 4 weeks. Alternatively, OVX mice were treated 
s.c. with 100μL of E2 (1µg/mouse; 0.04mg/kg/day) (n=9), G1 (5µg/mouse; 0.2mg/kg/day) 
(n=9) or vehicle (n=10). The activity of G1 at the chosen dose has earlier been shown in vivo 
[122, 123]. All groups received treatments 5 days per week for 4 weeks.  
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3.2.2 Metatarsal culture ex vivo 
After dissection, metatarsal bones were transferred to 24-well plates and cultured in 1 mL of 
phenol red-free and estrogen-free DMEM/F12 medium supplemented with 0.1% BSA, 1 mM 
β-glycerophosphate, 0.05 mg/mL ascorbic acid and 20 μg/mL gentamicin added at 37°C 
under a humidified atmosphere containing 5% CO2 following the protocol established by our 
group [124]. The bones were co-cultured with either vehicle (DMSO) or G1 (1, 10, 100 and 
300 nM) dissolved in DMSO. 
 
3.2.3 Body weight and uterus, femur and tibia measurements  
 
Body weight was measured at the beginning and the end of the experiment. Also, at the end of 
the experiment, mice were killed and uteruses were weighted. The length of the femur and tibia 
was measured ex vivo using a pocket vernier caliper (Helios-Preisser, Gammertingen, 
Germany). 
 
3.2.4 Immunofluorescence for the detection of the ERs and PCNA 
expression and TUNEL assay 
 
The femur and tibia were dissected out and fixed in 4% phosphate-buffered formalin for 24 h. 
Decalcification was done in 10% EDTA for 2 weeks and bones were stored in 70% ethanol. 
For histological analysis, tibias were embedded in paraffin. Five micrometer-thick sections 
were prepared from the paraffin blocks. Uteruses were collected and weighed prior to analysis. 
For immunohistochemistry, the tissue sections were deparaffinized for 40 min at 60°C, 
rehydrated in xylene, 100% ethanol, 95% ethanol and 75% ethanol, for 5 min in each solution 
and finally washed with water. Antigen retrieval was performed in sodium citrate buffer (10 
mM, pH 6.0) for 15 min at 95°C. After retrieval, the slides were incubated with 1.5% donkey 
serum in PBS for 1 h at room temperature (RT), with primary rabbit anti-PCNA antibody 
(1:250 dilution) overnight at 4°C and with secondary donkey anti-rabbit antibody (1:250 
dilution) for 1 h at RT. Nuclear staining with DAPI was performed for 15 min at RT. After the 
staining, the slides were mounted with Dako Fluorescence Mounting Medium. The TUNEL 
assay was performed on growth plate sections according to the manufacturer’s instructions. 
Briefly, apoptotic chondrocytes were identified by terminal deoxynucleotidyltransferase 
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(TdT)-mediated deoxy-UTP nick end labeling (TUNEL) immunohistochemistry applying the 
TdT-FragEL DNA fragmentation kit (Oncogene Research, Boston, MA, USA) as described 
previously by our group [125]. Alexa-546 (Invitrogen) (red fluorescence) positive cells 
represented apoptotic chondrocytes.  
 
3.2.5 Quantitative histology of mouse and human growth plate tissues  
Tibia growth plates were analyzed ex vivo. For quantitative histology of tibia growth plates, 5-
µm-thick paraffin-embedded tibia sections were prepared and stained with Alcian blue/van 
Gieson. The quantitative analysis was performed by measuring two-third of the growth plate 
sections at 10× magnification. Images were captured with a Nikon Eclipse E800 light 
microscope (Nikon) connected to the digital camera (Hamamatsu C4742-95, Hamamatsu City, 
Japan) with a digital color camera system (Olympus DP70). Olympus MicroImage software 
(version 4.0; Olympus Optical) was applied for imaging. The height of the whole tibia growth 
plates was calculated as an average of 20 measurements per growth plate. The height of the 
proliferative and the hypertrophic zones was measured in 20 columns per tibia growth plates 
and was presented as an average. Hypertrophic chondrocytes were defined as cells with height 
bigger than 7 µm. All the measurements were obtained in a blind manner by Image Pro Plus, 
version 6.3 software. 
The human growth plate tissue samples were fixed in 4% phosphate-buffered formalin for 24h, 
embedded in paraffin and 5 μm thick sections were prepared from the paraffin blocks. Images 
were captured with a Nikon Eclipse E800 light microscope (Nikon) connected to the digital 
camera. All measurements were made in a blind manner using the Image Pro Plus, version 6.3 
software. 
 
3.2.6 Quantitative histology of mouse metatarsal bones treated ex vivo 
Digital pictures were captured on day 0, 2, 5, 7, 9, 12 and 14 using a Hamamatsu C4742-95 
digital camera attached to a Nikon SMZ-U microscope. The length of each metatarsal bone 
was measured blindly using the ImageJ software (NIH). The increase in bone length was 
expressed as a delta of the length at the day of the dissection (day 0 = baseline). 
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3.2.7 Ex vivo treatment and RNA extraction  
Human growth plate tissue samples were obtained from patients with extremely tall stature and 
treated with 10nM E2 or vehicle in phenol red-free DMEM/F12 medium supplemented with 
0.1% BSA, 1 mM β-glycerophosphate, 0.05 mg/ml ascorbic acid and 20 μg/ml gentamicin 
added at 37°C under a humidified atmosphere containing 5% CO2 for 24 hours. Following the 
treatment, the tissue samples were divided in half and used for either RNA extraction or fixation 
and paraffin embedding. The isolation of mRNA from the growth plate tissues was performed 
using TRIzol Reagent (Invitrogen) and followed by the RNA-seq analysis.  
 
 
3.2.8 RNA-seq analysis 
Base-calling and demultiplexing were performed using Illumina Casava1.7 software. The data 
were mapped to hg19 genome (bowtie2-indexed reference downloaded from 
ftp://ftp.ccb.jhu.edu/pub/data/bowtie2_indexes/hg19.zip) with STAR software 2.5.2b with 
default parameters [126]. Read counts per gene were counted with the featureCounts tool 
(version 1.5.3) from the Subread package [127]. Differential expression analysis was done 
using DESeq2 package [128]. DESeq2 was applied to compare two models predicting the 
expression levels of each gene: the null model accounted for the patient, the non-trivial model 
used both patient identity and the presence of estradiol treatment as predictors in order . to 
account for the natural variance between patients. 
None of the genes passed the FDR<0.05 cutoff after Benjamini-Hochberg multiple testing 
correction, since the effect size was small. Nevertheless, we were able to conduct a GSEA-like 
gene set enrichment analysis with fGSEA package [129] using the results of the DESseq2 test. 
The further analysis targeted gene sets and pathways that were enriched by the genes activated 
or suppressed by E2 exposure. The fGSEA analysis was applied to investigate whether the 
genes in a particular set have either high or low ranks in gene list. As a reference database, we 
used MSigDB Hallmark gene set (human_H_v5p2, 
http://software.broadinstitute.org/gsea/msigdb/) [130]. 
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3.2.9 Statistical analysis 
 
In Paper I and II, the data were presented as means ± S.E.M., and the differences were calculated 
by one-way ANOVA using the SPSS software by multiple comparisons vs control group 
(Holm–Sidak method). ***P < 0.001, **P < 0.01 were considered as statistically significant. 
In Paper II and III,  Student t test was used for statistical analysis.  
Mean values ± standard deviations were presented. *P < 0.05 was considered as statistically 
significant. 
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4 RESULTS AND DISCUSSION 
4.1 THE EFFECTS OF LIGAND-ACTIVATED ERΑ AND ERΒ IN THE GROWTH 
PLATE 
In the Paper I, we have studied the actions of ligand-activated ERα and ERβ in the growth 
plate. We observed shorter tibiae and femur bones in both E2- and PPT-treated mice when 
compared to control mice, whereas treatment with DPN did not affect bone lengths. Moreover, 
mice treated with E2 or PPT had reduced growth plate height and hypertrophic zone height 
when compared to those treated with DPN, suggesting that the effect was mediated through 
ERα (Fig. 5). Notably, the hypertrophic zone showed higher reduction than the proliferative 
zone by either E2 or PPT treatment. Moreover, PCNA staining revealed suppressed 
proliferation of chondrocytes in the tibia growth plate in PPT- or E2-treated mice compared to 
controls. 
 
Figure 5. Effects of E2 and ERα and ERβ agonists on tibia growth plate length and proliferative 
and hypertrophic chondrocytes. Alcian blue/van Gieson staining of mouse proximal tibia growth 
plate. R = resting zone; P = proliferative zone and H = hypertrophic zone  
 
Our report of ERα-mediated regulation of bone growth is the first to show that activation of 
ER by a selective ligand induces inhibition of bone growth. This finding is in line with the 
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previous study demonstrating that the number of chondrocytes is diminished in mice with the 
expression of active mutant ERα in chondrocytes [131]. 
In contrast to the influence on the proliferation, no effects of a selective ERα agonist PPT on 
apoptosis were observed, though it was difficult to make a clear conclusion regarding apoptosis 
without gene expression analysis. Notably, apoptotic genes were earlier reported to be affected 
by ERα in bone [132]. In contrast, no changes in apoptosis were found in ERα-deficient mice 
when compared to WT mice [108]. The identification of E2-targeted genes in the study 
described by Paper III provided partial understanding of the potential targets of ERα, since it 
appears to be the main functional ER in the growth plate. 
Importantly, our results showed that despite the significant inhibition of bone growth, the 
selective ERα agonist PPT had only minor uterotropic effect. This finding suggested that in 
future studies one might choose to adjust the doses of PPT or another similar selective ERα 
agonist in order to selectively inhibit chondrocyte proliferation while being neutral towards 
uterus, ovaries and mammary glands. 
 
4.2 THE EFFECTS OF LIGAND-ACTIVATED GPER-1 ON BONE GROWTH 
In Paper II, we have studied if GPER-1 may regulate bone growth. Earlier studies have found 
the suppression of bone growth by E2 in WT mice but no effects in GPER-1-deficient mice 
[75]. Also, GPER-1 has been shown to influence transcription activation by E2 [133]. 
Moreover, inhibition of mesenchymal stem cell differentiation into chondrocytes has been 
demonstrated in vitro [134]. Therefore, we hypothesized that ligand-activated GPER-1 may 
affect chondrocyte proliferation in the growth plate. However, the results showed that none of 
the concentrations of G1 had a direct effect on metatarsal bone growth when compared to 
control. Similarly, G1 did not influence tibia and femur growth in treated mice (Fig. 6). Thus, 
our current study did not find any effects of the GPER-1 agonist G1 on the growth plate in ex 
vivo-treated metatarsal bones. 
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Figure 6. Effects of E2 and G1 on tibia and femur lengths. The study groups included ovariectomized 
mice treated with E2 (0.04 mg/kg/day), G1 (0.2 mg/kg/day) or vehicle alone and sham-operated mice. 
Vehicle vs E2, vehicle vs sham, **P < 0.01. Tibia length (A) and femur length (B) (n = 9–10). All the 
data are presented as means ± S.E.M., and the differences were calculated by one-way ANOVA. 
Studies of GPER-1 functions in the growth plate might have potential clinical applications, 
since GPER-1 was found to be expressed in both mouse and human chondrocytes [73, 135] 
and GPER-1-deficient mice had enhanced elevated bone mass and proliferation in the growth 
plate [121]. However, our ex vivo model revealed no direct actions of GPER-1 in the mouse 
growth plate in metatarsal bones. In line with this, ligand-mediated stimulation of GPER-1 did 
not show any effect on bone growth in vivo. Neither it affected growth plate chondrocyte 
proliferation or apoptosis. For our study, we choose the dose of G1, which was previously used 
in mouse models with clear systemic effects [123, 136]. 
Although GPER-1 does not seem to have any direct effects on chondrocyte proliferation in the 
growth plate, its potential interactions with other ERs expressed in the growth plate cannot be 
completely excluded until relevant studies would be performed. For instance, the potential 
cross-reactivity between GPER-1 with ERα [137]. Besides, ligand-independent actions of 
GPER-1 have been reported in ovarian tumor cells [138]. Thus, the findings of the Paper II did 
not reveal any effects of activated GPER-1 on bone growth. Our results indicate that E2 effects 
in bone and growth plate are mainly mediated via ERα. 
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4.3  IDENTIFICATION OF E2-TARGETED GENES AND SIGNALING 
PATHWAYS IN HUMAN GROWTH PLATE CHONDROCYTES 
In Paper III, we have identified multiple enriched pathways inhibited by E2 treatment, such 
as mTOR, estrogen response early and late, apoptosis, epithelial mesenchymal transition and 
angiogenesis (Fig. 7).  
 
Figure 7. Pathway enrichment analysis. Volcano plot showing the significantly upregulated and 
downregulated enriched pathways in control vs. E2 treated human growth plate tissues.  
Among the highly affected genes, peptide YY (PYY), which negatively regulates bone mineral 
density and bone mass, was significantly downregulated by E2 treatment. Since PYY-deficient 
mice showed increased osteoblast activity, PYY was suggested to inhibit osteoblast functions 
[139]. Moreover, overexpression of PYY suppressed osteoblasts via Y1 receptor-mediated 
MAPK activation. In addition, expression of Homeobox 7 (HOXB7), which stimulates 
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osteogenic differentiation of mesenchymal stem cells, was strongly inhibited by E2. HOXB7 
was shown to activate osteogenesis via RUNX2 [140]. 
Also, the mTOR signaling pathway was significantly inhibited by E2. Stimulation of mTOR 
has been reported to regulate chondrocyte proliferation and differentiation [39]. Furthermore, 
mTORC1 was found to control preosteoblast differentiation [141]. Moreover, our group has 
earlier demonstrated that activation of mTORC1 caused disorganization of the resting zone of 
the growth plate [142]. Furthermore, TGFβ1 also was among the genes suppressed by E2. 
TGFβ/BMP signaling is known to regulate osteoblast differentiation [30]. 
Ihh signaling pathway, which has a pivotal role in the regulation of the differentiation in the 
growth plate, also was among the significantly enriched pathways downregulated by E2 in 
human growth plate (Paper III, Fig. 1). These results are in line with earlier findings 
demonstrating the inhibition of Ihh genes by treatment with both the selective ERα agonist PPT 
and the selective ERβ agonist DPN in the rat uterus [143]. Furthermore, the bone growth has 
been found to depend on the interactions between Ihh and Wnt/β-catenin signaling pathways. 
Our study has revealed that Wnt/β-catenin signaling was also suppressed by E2 in the growth 
plate (Paper III, Fig. 1). Furthermore, AXIN2 expression was strongly inhibited by E2 
according to the RNAseq data. Axin2 has previously been shown to suppress maturation of 
osteoblasts via regulation of Wnt signaling [144]. Other pathways, which regulate bone growth 
and development and were downregulated by E2, include TGFβ, Notch and epithelial-
mesenchymal transition signaling [30, 145, 146]. 
The vascular network supplies the bone with cells, growth factors and minerals essential for 
growth, mineralization and development of extracellular matrix. Vascular endothelial growth 
factors (VEGF) directly regulate differentiation of osteoblasts and osteoclasts [147]. Our 
findings have revealed that treatment with E2 might suppress angiogenesis in the growth plate, 
since RNA-seq data indicated the suppression of VEGF-C, one of the main vasculogenic 
factors and angiogenesis was among the enriched pathways suppressed by E2 treatment (Fig. 
7). Furthermore, E2 was demonstrated to suppress VEGF expression and angiogenesis in tumor 
cells [148]. Therefore, VEGF-C might be another potential target of E2 for the regulation of 
bone growth. 
In addition, E2 significantly suppressed apoptosis in the growth plate as observed by RNA-seq 
analysis (Fig. 7). In line with this, TUNEL assay showed inhibition of apoptosis in growth plate 
tissue exposed to E2 when compared to control. 
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Since nuclear and membranous ERs are the direct targets of E2 in the growth plate, we have 
investigated whether the expression of these receptors may be affected by E2 treatment. The 
results of the immunofluorescence revealed that the treatment with E2 significantly suppressed 
the expression of both ER and GPER-1. These data might be explained by potential 
compensatory downregulation of ER expression as a consequence of E2 treatment. To 
summarize, the results of Paper III identified target genes and pathways affected by E2 in 
human growth plate. Notably, several signaling pathways, which are vital for bone 
development and growth, were suppressed by E2 treatment. 
4.4 STUDY LIMITATIONS 
 
There are several limitations of our studies due to the observed differences in E2 effects in mice 
and humans, potential interactions between different ERs within the growth plate, previously 
reported ligand-independent actions of the ERs and limited number of clinical samples 
analyzed by RNA-seq. 
Extrapolation of these results obtained in experimental animals to humans should be done with 
caution, since high doses of E2 cause growth plate closure in humans but not in mice [149]. As 
to the results described in Paper I, considering ligand-mediated activation of ERα for 
therapeutic purposes, toxicological evaluation would be required, since ERα has shown 
potential involvement in tumorigenesis in breast cancer development [150].  
With regard to the second study described in Paper II, the potential interactions of GPER-1 
with other ERs should be taken into account, since GPER-1 has been shown to affect ERα. 
Furthermore, GPER-1 might function in a ligand-independent fashion in the bone. In particular, 
GPER-1 was reported to activate proliferation in ovarian cells [138]. 
Though we identified a number of genes and related signaling pathways influenced by E2 in 
the human growth plate in the study described in Paper III, additional studies are required to 
verify the key regulatory mechanisms of these E2 effects. Besides, RNA-seq data from only 
two patients were included in Paper III. The analysis of larger groups of patients would be 
expected as a continuation of our studies. Furthermore, the growth plate samples were treated 
ex vivo, and there might be differences in gene expression changes between experimental data 
and gene expression alterations happening in patients. Moreover, the concentration of E2 for 
the treatment of growth plate samples was selected as the most common dose of E2 in the ex 
vivo and in vitro studies. Notably, treatment with high doses of E2 would not be appropriate to 
use in vivo as these doses might cause cancerogenic effects. In addition, we chose only one 
dose of E2 for the ex vivo experiments since tissue materials were limited, although testing a 
range of E2 concentrations would be important.  
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5 CONCLUSIONS 
5.1 PAPER I 
 
 Our in vivo data in mice showed that the growth suppressive effects were mainly 
mediated via ERα.  
 Treatment with E2 or PPT decreased growth plate height while ligand stimulation of 
ERβ did not influence growth plate height.  
 
5.2 PAPER II 
 
 Our results showed that the selective GPER-1 agonist G1 had no local effect on 
metatarsal bone growth when treated ex vivo. 
 In vivo studies in mice confirmed that G1 did not affect tibia or femur growth when 
administered systemically.  
 We conclude that ligand stimulation of GPER-1 does not affect bone growth and 
growth plate cartilage in these models. 
 
5.3 PAPER III 
 
 Target genes and signaling pathways affected by E2 were identified in cultured rare 
specimens of human growth plate cartilage.  
 Enriched pathways inhibited by E2 included mTOR, estrogen response early, 
apoptosis, epithelial mesenchymal transition and angiogenesis. 
 The expression of peptide YY, a negative regulator of bone formation and mineral 
density, was inhibited by E2 treatment. 
 
Our results open for the development of novel therapies of growth disorders. Estrogen signaling 
plays an important role in the regulation of longitudinal bone growth originating from the 
growth plate. High doses of E2 were demonstrated to inhibit bone growth. Although several 
ERs were shown to be expressed in the growth plate, ERα is suggested to be the main ER 
mediating the E2 effects on bone growth. Both clinical data and studies using ER-deficient 
mouse models indicated that the effects of E2 in bone are mediated via ER. Regarding the 
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functions of other ERs analyzed in Papers I and II, treatment with selective ERβ and GPER-
1 agonists did not show any significant effects on the proliferation in the growth plate. 
Nevertheless, ligand-independent effects of these ERs might still influence chondrocyte 
activity.  
Altogether, these data suggest that selectively targeting ERα can provide an effective treatment 
of bone growth disorders characterized by excessive tall stature.  
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6 FUTURE PERSPECTIVES 
Several research directions can be developed based on our current results. Our studies in Paper 
I have demonstrated that ERα is the main ER, which regulates longitudinal bone growth. 
However, the target genes and signaling pathways involved in bone growth regulation via ERα 
remain to be identified. Gene expression studies, such as RNA sequencing, could be used to 
detect target genes regulated via ERα in the growth plate. Considering the negative side-effects 
known to be associated with E2 treatment, further preclinical studies of selective ERα agonists 
should be performed prior to any clinical studies exploring their effectiveness and safety in 
extremely tall adolescents. 
The study described in Paper III has identified several target genes and enriched pathways 
affected by E2. Future studies could include investigation of the specific mechanisms involving 
identified genes and verification of those mechanisms using in vitro and in vivo experimental 
models. Furthermore, additional studies are required to confirm gene expression changes in a 
large cohort of patients. Also, a comparison of gene expression profiles in normal human 
growth plate and growth plate from individuals with tall stature would be important for the 
understanding of mechanisms regulating longitudinal bone growth. 
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